- Home
- SI vs STRO Comparison
SI vs STRO Comparison
Compare SI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | STRO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.2M | 332.8M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SI | STRO |
|---|---|---|
| Price | $18.18 | $11.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $26.50 | ★ $47.23 |
| AVG Volume (30 Days) | 98.4K | ★ 266.4K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,317,000.00 | $38,419,000.00 |
| Revenue This Year | $44.61 | N/A |
| Revenue Next Year | $29.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.63 | N/A |
| 52 Week Low | $10.92 | $0.72 |
| 52 Week High | $24.60 | $43.85 |
Technical Indicators
Market Signals| Indicator | SI | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 28.47 |
| Support Level | $17.69 | $10.52 |
| Resistance Level | $20.03 | $16.99 |
| Average True Range (ATR) | 0.91 | 1.24 |
| MACD | 0.08 | -0.21 |
| Stochastic Oscillator | 36.18 | 15.95 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.